Physician profile
Michael Alocci
NPI 1487634531
$3,489.15
in general payments reported to CMS, 2019-2025
28 companies · $233 in 2025
The $233 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $612 · 2020: $433 · 2021: $284 · 2022: $588 · 2023: $590 · 2024: $750 · 2025: $233.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,573.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,573.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $744.22 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Pfizer INC. | $512.56 | 2019-2024 | |
| Glaxosmithkline, LLC. | $383.29 | 2019-2024 | Trelegy Ellipta |
| Novo Nordisk INC | $275.60 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $251.97 | 2019-2021 | |
| Abbott Laboratories | $198.74 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Bayer Healthcare Pharmaceuticals INC. | $172.02 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $124.09 | 2019-2023 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.56 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $90.30 | 2023-2025 | Eliquis, Camzyos |
| Daiichi Sankyo INC. | $88.39 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $72.38 | 2023 | Gemtesa |
| Amarin Pharma, INC. | $70.74 | 2019-2021 | |
| Esperion Therapeutics, INC. | $61.15 | 2024 | Nexletol |
| Janssen Pharmaceuticals, INC | $57.09 | 2019-2023 | Xarelto |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $52.23 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $40.04 | 2022-2024 | Gardasil, Gardasil 9 |
| Novartis Pharmaceuticals Corporation | $26.36 | 2019-2020 | |
| Allergan, INC. | $25.08 | 2020 | |
| Dexcom, INC. | $24.73 | 2025 | Dexcom G6 Transmitter |
| Sunovion Pharmaceuticals INC. | $22.29 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $21.30 | 2024 | Sohonos |
| Exact Sciences Corporation | $15.78 | 2023 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $15.29 | 2024 | Voquezna |
| Avanir Pharmaceuticals, INC. | $14.79 | 2019 | |
| Lilly USA, LLC | $13.99 | 2020 | |
| Idorsia Pharmaceuticals US INC | $13.34 | 2022 | |
| Amgen INC. | $10.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Alocci listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.